Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Huang

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
The Lancet. Oncology|July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialConstantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
The New England Journal of Medicine|December 8, 2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C Byrd, Bonnie Harrington, Susan O'Brien, et al.
JCO Oncology Practice|November 17, 2022
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic CancerMichael F Gensheimer, Divya Gupta, Manali I Patel, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.
Frontiers in Immunology|March 21, 2022
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
The Lancet. Oncology|July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialConstantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
The New England Journal of Medicine|December 8, 2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C Byrd, Bonnie Harrington, Susan O'Brien, et al.
JCO Oncology Practice|November 17, 2022
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic CancerMichael F Gensheimer, Divya Gupta, Manali I Patel, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.
Frontiers in Immunology|March 21, 2022
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, et al.
Pageof 13